Edition:
United States

Valneva SE (VLS.PA)

VLS.PA on Paris Stock Exchange

2.49EUR
11:35am EDT
Change (% chg)

€0.00 (+0.00%)
Prev Close
€2.49
Open
€2.50
Day's High
€2.52
Day's Low
€2.49
Volume
55,420
Avg. Vol
156,036
52-wk High
€3.55
52-wk Low
€1.96

Latest Key Developments (Source: Significant Developments)

Valneva FY EBITDA turns to profit of EUR 2.8 mln
Thursday, 23 Mar 2017 02:01am EDT 

Valneva SE : Total revenues and grants of 97.9 million euros ($105.64 million) in 2016 (versus 83.3 million euros in 2015) . Valneva reported a positive EBITDA of 2.8 million euros in 2016 (versus EBITDA loss of 8.5 million euros in 2015) . Net loss of 49.2 million euros in 2016, impacted by impairment charges related to pseudomonas program termination . Expects 2017 overall IFRS revenues to reach 105 to 115 million euros, reflecting up to 17 percent total revenue growth compared to 2016 . Positive operating cash flow of 6.5 million euros in 2016 . Anticipates product sales in 2017 to grow by 10-15 percent over 80.4 million euros reported in 2016 . Expects to further grow its operational performance to an EBITDA of 5 to 10 million euros in 2017 . To receive a 5 million euro installment from European Investment Bank loan .Intends to invest between 21 million euros and 23 million euros in research and development, corresponding to approximately 20 percent of annual revenues.  Full Article

Valneva revenues and grants increased by 17.5%
Thursday, 23 Feb 2017 01:02am EST 

Valneva Se : Revenues and grants increased by 17.5% year-on-year and amounted to €97.9 million in 2016 (versus €83.3 million in 2015); . Valneva reported a positive estimated EBITDA of €2.8 million in 2016 (versus. An EBITDA loss of €8.5 million in 2015) . Cash position of €42.2 million at the end of 2016 further strengthened by equity financing proceeds of €7.5 million in q4; . Expects 2017 overall IFRS revenues to reach €105 to €115 million, reflecting up to 17% total revenue growth compared to 2016; . Company anticipates product sales this year to grow by 10-15% over the €80.4 million reported in 2016, driven mainly by ixiaro/jespect and dukoral .Group expects to further grow its operational performance to an ebitda of €5 to €10 million in 2017 while still investing approximately 20% of annual revenues in R&D.  Full Article

Valneva announces closing of private placement by MVM Life Science Partners
Friday, 16 Dec 2016 01:46am EST 

Valneva SE : Announced on Thursday closing of private placement in connection with 15.2 million euros ($15.9 million)investment by MVM Life Science Partners . MVM's investment consists of a combined purchase of new shares together with a tranche of shares from existing undisclosed shareholders of Valneva . Valneva now completed the issuance of 2,884,615 new ordinary shares to funds managed by MVM by way of a private placement without preferential subscription rights . Placement resulted in aggregate proceeds of 7.5 million euros for Valneva .The total number of ordinary shares has increased to 77,582,714..  Full Article

Valneva receives FDA and European approvals to start clinical testing of lyme disease vaccine candidate
Friday, 9 Dec 2016 01:00am EST 

Valneva SE :Receives FDA and European approvals to start clinical testing of lyme disease vaccine candidate.  Full Article

Valneva H1 EBITDA turns to 4.7 mln euro profit
Wednesday, 31 Aug 2016 01:14am EDT 

Valneva SE : Reports strong revenue growth and positive EBITDA in H1 2016 . EBITDA improved to 4.7 million euros ($5.2 million) in H1 2016 (versus a loss of 5.3 million euros H1 2015) . H1 revenue 51.4 million euros versus 39.2 million euros year ago . Q2 net loss is 34.4 million euros versus loss of 8.8 million euros a year ago . Re-Affirms its FY 2016 financial outlook .2016 IFRS revenues expected to reach 90-100 million euros, with product sales between 70-80 million euros - reflecting up to 30 pct growth over 2015 product sales.  Full Article

Valneva reports strong revenue growth and positive EBITDA in H1 2016
Wednesday, 31 Aug 2016 01:09am EDT 

Valneva Se :Valneva reports strong revenue growth and positive EBITDA in H12016.  Full Article

Valneva confirms its growth strategy and financial outlook
Friday, 1 Jul 2016 01:00am EDT 

Valneva SE : Announces successful outcome of its agm; confirms its growth strategy and financial outlook . Confirmed its FY 2016 financial target of reaching 90 million euros to 100 million euros in revenues and coming close to EBITDA breakeven . Reiterated its strategy to grow revenues to around 250 million euros by 2020 . Expects to find a partner for phase III trial of its clostridium vaccine candidate before end of year . Expects to enter its lyme vaccine candidate in phase I in second half of 2016 . Expects to announce proof-of-concept results for development of a zika vaccine in coming months . Renewed its equity line with Crédit Agricole CIB . New equity line, which replaces a previous instrument expired in May 2016, will enable Valneva to issue up to 5,474,633 new ordinary shares representing up to 7.33 pct of its ordinary share capital .Based on current share price, amount of equity that could be raised through this equity line could reach approximately 11 million euros.  Full Article

Valneva Q1 net result turns to loss of 5.0 million euros
Wednesday, 11 May 2016 01:08am EDT 

Valneva SE : Q1 total revenues and grants were €24.7 million ($28.11 million) in Q1 2016 (versus €19.5 million in Q1 2015) . Q1 operating loss improved to €2.7 million (versus €3.7 million in Q1 2015) . Q1 net loss was €5.0 million (compared to adjusted net profit of €9.8 million in Q1 2015) . Cash position at €33.4 million at end of March 2016 . Confirms its FY 2016 financial outlook . 2016 IFRS revenues expected to reach €90 to €100 million, with product sales between €70 and €80 million .Says will continue to strive towards financial self-sustainability and expects to reduce its EBITDA loss to less than €5 million in 2016 while continuing to invest around €25 million in R&D.  Full Article

Valneva reports 2016 guidance in line with analysts' estimates
Monday, 21 Mar 2016 02:00am EDT 

Valneva SE:Expects 2016 overall IFRS revenues to reach 90 to 100 million euros with product sales in expected range of 70 to 80 million euros.FY 2016 revenue: 98.53 million euros - Thomson Reuters I/B/E/S.Company anticipates continued growth of Ixiaro /Jespect sales to approximately 50 million euros in 2016, up from 30.6 million euros in 2015.Improved revenues due to Valneva's new global marketing & distribution network are expected to lead to a gross margin on product sales of approximately 50 pct in 2016.Expects to reduce its EBITDA loss to less than 5 million euros in 2016 while continuing to invest around 25 million euros in research and development.Envisions growing its revenues to approximately 250 million euros in 2020 through existing and future products.Long term company will continue to build on value growth from research and development and anticipates investing at least 20 pct of its revenues annually in an innovative research and development pipeline.  Full Article

Valneva announces $42 mln Ixiaro supply contract with DoD
Wednesday, 16 Mar 2016 03:45am EDT 

Valneva SE:Valneva announces $42 million IXIARO supply contract with US government.Valneva will supply IXIARO doses to the defense logistics agency (DLA), supply center of the Us Department of Defense.  Full Article

More From Around the Web

BRIEF-Valneva FY EBITDA turns to profit of EUR 2.8 mln

* Total revenues and grants of 97.9 million euros ($105.64 million) in 2016 (versus 83.3 million euros in 2015)